What happened
Genentech/Roche: 16 abstracts, updated data on trontinemab (Brainshuttle, phase Ib/IIa, rapid amyloid clearance), the design of the phase III PrevenTRON trial in preclinical Alzheimer's (already recruiting) and the launch of the phase II TARBELA-AD trial with RG6434, an oral NLRP3 inhibitor against neuroinflammation.
Alzheon: launch of ORION-E4, a second phase III of oral valiltramiprosate (ALZ-801) in APOE4/4 carriers with mild cognitive impairment — about 550 people, 78 weeks — after analyses of APOLLOE4 showed fewer spontaneous cerebral microhaemorrhages (ARIA-H) with the drug.
Biomed Industries: four posters on NA-831, an investigational oral candidate based on the neurogenesis hypothesis. A randomised, placebo-controlled phase 2, 24 weeks, 112 participants with mild cognitive impairment or Alzheimer's dementia: a 4.1-point benefit on ADAS-Cog-13 versus placebo (p=0.001), with generally favourable tolerability.
Why it matters
CTAD is where Alzheimer's drug development is judged each year, and this edition keeps growing: an anti-amyloid shuttle, an anti-inflammatory pill, a second oral anti-amyloid aggregation inhibitor and a neurogenesis candidate — four different mechanisms in one conference.
What comes next
The data arrive at CTAD, 16–19 November in Boston. The Age Vanguard will report the results as they are presented — trontinemab, ORION-E4 and the NA-831 posters among them.
Agenda, not results — the data arrive at CTAD, not today. NA-831 is a company announcement, not a peer-reviewed paper: 112 people, 24 weeks. Read it as 'to follow', not as a confirmed result.